Biliary Tract Cancer Market Spotlight Report 2021 - ResearchAndMarkets.com

·3 min read

DUBLIN, January 27, 2022--(BUSINESS WIRE)--The "Market Spotlight: Biliary Tract Cancer" report has been added to ResearchAndMarkets.com's offering.

Biliary tract cancer (BTC), also known as cholangiocarcinoma or bile duct adenocarcinoma, is a cancer that originates from the cells which line the bile duct. These are a group of rare and heterogeneous malignancies with poor prognosis. BTCs are genetically and clinically divergent.

Key Takeaways

  • The publisher estimates that in 2019, there were approximately 405,800 incident cases of biliary tract cancer (BTC) worldwide, and forecasts that number to increase to 433,300 incident cases by 2028.

  • The only approved drug in the BTC space is Pemazyre, which targets fibroblast growth factor receptor. It is administered via the oral route.

  • The majority of industry-sponsored drugs in active clinical development for BTC are in Phase II, with one drug in the NDA/BLA stage.

  • Therapies in development for BTC focus on a wide variety of targets, with the majority being administered via the oral or intravenous routes.

  • High-impact upcoming events for drugs in the BTC space comprise topline Phase II trial results for M7824 and fimaCHEM, topline Phase IIa trial results for Xermelo, topline Phase IIb/III trial results for surufatinib, topline Phase III trial results for Imfinzi, an expected CHMP opinion for Pemazyre, and an estimated PDUFA date for infigratinib.

  • The overall likelihood of approval of a Phase I solid tumors asset is 5.5%, and the average probability a drug advances from Phase III is 42.7%. Drugs, on average, take 9.7 years from Phase I to approval, compared to 9.6 years in the overall oncology space.

  • The distribution of clinical trials across Phase I-IV indicates that the vast majority of trials for biliary tract neoplasms have been in the early and mid-phases of development, with 91% of trials in Phase I-II, and only 9% in Phase III-IV.

  • The US has a substantial lead in the number of biliary tract neoplasms clinical trials globally. The UK leads the major European markets, while South Korea has the top spot in Asia.

  • Eli Lilly has the highest number of completed clinical trials for biliary tract neoplasms, with five trials.

  • AstraZeneca leads industry sponsors with the highest overall number of clinical trials for biliary tract neoplasms.

Key Topics Covered:

OVERVIEW

KEY TAKEAWAYS

DISEASE BACKGROUND

  • Subtypes

TREATMENT

  • Surgery

  • Radiation therapy

  • Chemotherapy

  • Targeted therapy

  • Palliative therapy

EPIDEMIOLOGY

MARKETED DRUGS

PIPELINE DRUGS

RECENT EVENTS AND ANALYST OPINION

  • Futibatinib for BTC (April 11, 2021)

  • Bintrafusp Alfa for BTC (March 16, 2021)

  • Tibsovo for BTC (January 17, 2021)

  • Tibsovo for BTC (September 21, 2020)

  • Varlitinib for BTC (November 11, 2019)

KEY UPCOMING EVENTS

KEY REGULATORY EVENTS

  • Japan Approves Incyte's Pemazyre for Unresctable BTC

  • Real-Time Review: Danyelza, Gavreto Graduate; infigratinib Joins Up

  • Merck KGaA Rebounds After COVID-19 Lockdowns

PROBABILITY OF SUCCESS

LICENSING AND ASSET ACQUISITION DEALS

  • Agios Sells Cancer Portfolio To Servier To Focus On Genetic Diseases

  • Lexicon Sells Cancer Supportive Care Therapy To TerSera

  • Sirnaomics To Use Precision NanoSystems Technology To Advance Pipeline

REVENUE OPPORTUNITY

CLINICAL TRIAL LANDSCAPE

  • Sponsors by status

  • Sponsors by phase

  • Recent events

BIBLIOGRAPHY

APPENDIX

For more information about this report visit https://www.researchandmarkets.com/r/2d1dey.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220127005832/en/

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting